Quince Therapeutics (QNCX) The Citizens JMP Life Sciences Conference 2025 summary

Technology and therapeutic approach

• Utilizes autologous red blood cells to encapsulate dexamethasone sodium phosphate, enabling chronic steroid delivery with reduced toxicity risks.

• The encapsulation process, called AIDE, uses a specialized machine and hypotonic/hypertonic solutions to load drugs into red blood cells.

• The technology allows for a high initial Cmax and prolonged receptor exposure, avoiding plasma toxicity thresholds.

• Safety data show no steroid toxicity in children treated monthly for up to 13 years.

• The platform could be adapted for other drugs and rare or non-rare diseases.

Lead program and clinical development

• Lead indication is Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved therapies and about 5,000 U.S. patients.

• Phase III placebo-controlled trial is ongoing, focusing on children aged 6–9, with about 60% enrollment and completion expected in 4Q.

• The trial uses a Special Protocol Assessment with the FDA, allowing for potential approval based on a single positive study.

• Previous phase II data showed a 28% improvement over placebo in the target age group, with a p-value of 0.009.

• The primary endpoint is a subset of the ICARS neurological score, focused on gait and posture, with meaningful clinical impact.

Commercial and financial outlook

• Estimated U.S. patient population is 4,600, with a combined U.S./EU population of about 10,000.

• Comparable rare disease therapies are priced at $400,000–$700,000 per year, suggesting a billion-dollar market opportunity.

• Cash runway extends into 2026, covering the period beyond phase III data readout.

• The company operates with a small, distributed team and acquired the technology from an Italian firm.